• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定凝血因子Xa肝素结合外位点中对肝素和凝血因子Va结合至关重要的碱性残基。

Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding.

作者信息

Rezaie A R

机构信息

Edward A. Doisy Department of Biochemistry, St. Louis University School of Medicine, St. Louis, Missouri 63104, USA.

出版信息

J Biol Chem. 2000 Feb 4;275(5):3320-7. doi: 10.1074/jbc.275.5.3320.

DOI:10.1074/jbc.275.5.3320
PMID:10652320
Abstract

We recently demonstrated that a template mechanism makes a significant contribution to the heparin-accelerated inactivation of factor Xa (FXa) by antithrombin at physiologic Ca(2+), suggesting that FXa has a potential heparin-binding site. Structural data indicate that 7 of the 11 basic residues of the heparin-binding exosite of thrombin are conserved at similar three-dimensional locations in FXa. These residues, Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) were substituted with Ala in separate constructs in Gla domainless forms. It was found that all derivatives cleave Spectrozyme FXa with similar catalytic efficiencies. Antithrombin inactivated FXa derivatives with a similar second-order association rate constant (k(2)) in both the absence and presence of pentasaccharide. In the presence of heparin, however, k(2) with certain mutants were impaired up to 25-fold. Moreover, these mutants bound to heparin-Sepharose with lower affinities. Heparin concentration dependence of the inactivation revealed that only the template portion of the cofactor effect of heparin was affected by the mutagenesis. The order of importance of these residues for binding heparin was as follows: Arg(240) > Lys(236) > Lys(169) > Arg(165) > Lys(96) > Arg(93) >/= Arg(125). Interestingly, further study suggested that certain basic residues of this site, particularly Arg(165) and Lys(169), play key roles in factor Va and/or prothrombin recognition by FXa in prothrombinase.

摘要

我们最近证明,在生理钙(Ca²⁺)条件下,一种模板机制对抗凝血酶使因子Xa(FXa)失活的肝素加速作用有显著贡献,这表明FXa有一个潜在的肝素结合位点。结构数据表明,凝血酶肝素结合外位点的11个碱性残基中的7个在FXa中处于相似的三维位置保守存在。这些残基,即精氨酸(Arg)93、赖氨酸(Lys)96、精氨酸125、精氨酸165、赖氨酸169、赖氨酸236和精氨酸240,在无Gla结构域形式的单独构建体中被丙氨酸(Ala)取代。结果发现,所有衍生物切割Spectrozyme FXa的催化效率相似。在不存在和存在五糖的情况下,抗凝血酶使FXa衍生物失活的二级缔合速率常数(k₂)相似。然而,在肝素存在的情况下,某些突变体的k₂受损高达25倍。此外,这些突变体与肝素-琼脂糖的结合亲和力较低。肝素失活的浓度依赖性表明,只有肝素辅因子效应的模板部分受到诱变的影响。这些残基对肝素结合的重要性顺序如下:精氨酸240>赖氨酸236>赖氨酸169>精氨酸165>赖氨酸96>精氨酸93≥精氨酸125。有趣的是,进一步的研究表明,该位点的某些碱性残基,特别是精氨酸165和赖氨酸169,在凝血酶原酶中FXa对因子Va和/或凝血酶原的识别中起关键作用。

相似文献

1
Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding.鉴定凝血因子Xa肝素结合外位点中对肝素和凝血因子Va结合至关重要的碱性残基。
J Biol Chem. 2000 Feb 4;275(5):3320-7. doi: 10.1074/jbc.275.5.3320.
2
Heparin-binding exosite of factor Xa.凝血因子Xa的肝素结合外位点
Trends Cardiovasc Med. 2000 Nov;10(8):333-8. doi: 10.1016/s1050-1738(01)00070-6.
3
Localization of the heparin binding exosite of factor IXa.凝血因子IXa肝素结合外位点的定位
J Biol Chem. 2002 Dec 27;277(52):50756-60. doi: 10.1074/jbc.M208485200. Epub 2002 Oct 22.
4
Role of the alpha-helix 163-170 in factor Xa catalytic activity.α-螺旋163-170在凝血因子Xa催化活性中的作用。
J Biol Chem. 2007 Oct 26;282(43):31569-79. doi: 10.1074/jbc.M704837200. Epub 2007 Aug 28.
5
Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa.钙通过模板机制增强抗凝血酶与因子Xa反应中的肝素催化作用。有证据表明钙可减轻肝素与因子Xa结合时Gla结构域的拮抗作用。
J Biol Chem. 1998 Jul 3;273(27):16824-7. doi: 10.1074/jbc.273.27.16824.
6
Ixolaris: a factor Xa heparin-binding exosite inhibitor.依诺肝素:一种Xa因子肝素结合外位点抑制剂。
Biochem J. 2005 May 1;387(Pt 3):871-7. doi: 10.1042/BJ20041738.
7
Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site.凝血因子Va上靠近精氨酸506激活蛋白C裂解位点的凝血因子Xa结合位点的特征分析。
J Biol Chem. 2007 Jul 27;282(30):21848-55. doi: 10.1074/jbc.M702192200. Epub 2007 Jun 6.
8
Definition of a factor Va binding site in factor Xa.凝血因子Xa中因子Va结合位点的定义。
J Biol Chem. 2001 Feb 16;276(7):5123-8. doi: 10.1074/jbc.M006961200. Epub 2000 Nov 21.
9
Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition.鉴定与蛋白Z依赖性蛋白酶抑制剂相互作用至关重要的凝血因子Xa残基:抑制作用需要活性位点和外位点相互作用。
J Biol Chem. 2005 Sep 23;280(38):32722-8. doi: 10.1074/jbc.M505517200. Epub 2005 Aug 3.
10
Factor Va alters the conformation of the Na+-binding loop of factor Xa in the prothrombinase complex.因子Va改变凝血酶原酶复合物中因子Xa的钠离子结合环构象。
Biochemistry. 2008 Jun 3;47(22):5976-85. doi: 10.1021/bi800319r. Epub 2008 May 6.

引用本文的文献

1
Andexanet Alfa-Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives.心脏手术中阿哌沙班相关的肝素抵抗:机制及体外研究视角
Arterioscler Thromb Vasc Biol. 2025 Jan;45(1):144-156. doi: 10.1161/ATVBAHA.124.321650. Epub 2024 Nov 21.
2
Regulation of Peptidase Activity beyond the Active Site in Human Health and Disease.蛋白酶活性的调节:超越人类健康与疾病中的活性位点。
Int J Mol Sci. 2023 Dec 4;24(23):17120. doi: 10.3390/ijms242317120.
3
Designing Smaller, Synthetic, Functional Mimetics of Sulfated Glycosaminoglycans as Allosteric Modulators of Coagulation Factors.
设计更小的、合成的、功能性的硫酸化糖胺聚糖类似物作为凝血因子的别构调节剂。
J Med Chem. 2023 Apr 13;66(7):4503-4531. doi: 10.1021/acs.jmedchem.3c00132. Epub 2023 Mar 31.
4
Investigating RNA-protein recognition mechanisms through supervised molecular dynamics (SuMD) simulations.通过监督分子动力学(SuMD)模拟研究RNA-蛋白质识别机制。
NAR Genom Bioinform. 2022 Nov 29;4(4):lqac088. doi: 10.1093/nargab/lqac088. eCollection 2022 Dec.
5
Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding.凝血因子 Va 的关键相互作用残基和区域,用于凝血酶原酶的组装和凝血酶原的结合。
J Thromb Haemost. 2019 Aug;17(8):1229-1239. doi: 10.1111/jth.14487. Epub 2019 Jun 17.
6
Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.硫酸化非糖基化糖胺聚糖类似物作为用于各种病理的新型药物发现平台。
Curr Med Chem. 2020;27(21):3412-3447. doi: 10.2174/0929867325666181120101147.
7
Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin.质谱分析揭示了糖胺聚糖链在抗凝血酶灭活因子Xa过程中的多方面作用。
Biochemistry. 2018 Aug 14;57(32):4880-4890. doi: 10.1021/acs.biochem.8b00199. Epub 2018 Jul 25.
8
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.适配体与药物联合用于心肺转流术的可逆抗凝。
Nat Biotechnol. 2018 Aug;36(7):606-613. doi: 10.1038/nbt.4153. Epub 2018 Jun 4.
9
Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.通过对Xa因子酶原性进行选择性调节产生的具有广泛适用性的止血剂。
Blood. 2015 Jul 2;126(1):94-102. doi: 10.1182/blood-2015-03-634329. Epub 2015 Apr 20.
10
Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene.一名凝血因子X基因中缺少天冬氨酸-185密码子的出血患者凝血缺陷的分子基础。
Thromb Res. 2014 Nov;134(5):1103-9. doi: 10.1016/j.thromres.2014.08.004. Epub 2014 Aug 20.